Likewise, the expression of NK CD16+56+ receptor molecules have been analyzed to identify reliable clinical response biomarkers in patients with RA receiving rituximab therapy to control the effects of the treatment. This evidence concerns the gene FCGR3A and rheumatoid arthritis.